In breast cancer, in vivo CCL5 neutralization or CCR5 antagonism were shown to abrogate the MSC-induced metastasis of cancer cells thus implicating CCL5/CCR5 as a key axis in this malignancy [21]. The gene discussed is CCL5; the disease is breast carcinoma.